Cardiovascular risk factors in children and adolescents with congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Version of Record online: 8 JUL 2013
© 2013 The Authors. Clinical Endocrinology published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Volume 80, Issue 4, pages 471–477, April 2014
How to Cite
Subbarayan, A., Dattani, M. T., Peters, C. J. and Hindmarsh, P. C. (2014), Cardiovascular risk factors in children and adolescents with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clinical Endocrinology, 80: 471–477. doi: 10.1111/cen.12265
- Issue online: 10 MAR 2014
- Version of Record online: 8 JUL 2013
- Accepted manuscript online: 10 JUN 2013 01:46AM EST
- Manuscript Accepted: 4 JUN 2013
- Manuscript Revised: 10 MAY 2013
- Manuscript Revised: 26 MAR 2013
- Manuscript Received: 26 FEB 2013
- 19National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and, Adolescents. (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics, 114(2 Suppl 4th Report), 555–576.
- 20Report of the Second Task Force on Blood Pressure Control in Children. (1987) Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland. Pediatrics, 79, 1–25.
- 22Craig, R. & Mindell, J. eds. (2011) Health survey for England 2010. NHS Information Centre, London.
- 272007) Cardiovascular risk factors and ultrasound evaluation of intima-media thickness at common carotids, carotid bulbs, and femoral and abdominal aorta arteries in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Journal of Clinical Endocrinology and Metabolism, 92, 1015–1018., , et al. (
- 292010) A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia. Clinical Endocrinology (Oxf), 72, 441–447., , et al. (